Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus PRAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus PRAZEPAM.
CENTRAX vs PRAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Prazepam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
10-30 mg orally, 3-4 times daily.
10-30 mg orally 3-4 times daily; maximum daily dose 60 mg.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Clinical Note
moderatePrazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate."
Clinical Note
moderatePrazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Cyclosporine
Terminal elimination half-life: 36-200 hours (mean ~75 hours). Long half-life leads to accumulation with repeated dosing and prolonged sedation, especially in elderly or hepatic impairment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Primarily renal (as conjugated metabolites, mainly oxazepam glucuronide): ~95%; fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Prazepam."